<?xml version='1.0' encoding='utf-8'?>
<document id="19845434"><sentence text="Comparison of mechanism-based inhibition of human cytochrome P450 2C19 by ticlopidine, clopidogrel, and prasugrel."><entity charOffset="74-85" id="DDI-PubMed.19845434.s1.e0" text="ticlopidine" /><entity charOffset="87-98" id="DDI-PubMed.19845434.s1.e1" text="clopidogrel" /><entity charOffset="104-113" id="DDI-PubMed.19845434.s1.e2" text="prasugrel" /><pair ddi="false" e1="DDI-PubMed.19845434.s1.e0" e2="DDI-PubMed.19845434.s1.e0" /><pair ddi="false" e1="DDI-PubMed.19845434.s1.e0" e2="DDI-PubMed.19845434.s1.e1" /><pair ddi="false" e1="DDI-PubMed.19845434.s1.e0" e2="DDI-PubMed.19845434.s1.e2" /><pair ddi="false" e1="DDI-PubMed.19845434.s1.e1" e2="DDI-PubMed.19845434.s1.e1" /><pair ddi="false" e1="DDI-PubMed.19845434.s1.e1" e2="DDI-PubMed.19845434.s1.e2" /></sentence><sentence text="Mechanism-based inhibition of CYP2C19 in human liver microsomes by the thienopyridine antiplatelet agents clopidogrel, prasugrel and their thiolactone metabolites was investigated by determining the time- and concentration-dependent inhibition of the activity of S-mephenytoin 4'-hydroxylase as typical CYP2C19 activity and compared with ticlopidine and its metabolite"><entity charOffset="71-85" id="DDI-PubMed.19845434.s2.e0" text="thienopyridine" /><entity charOffset="106-117" id="DDI-PubMed.19845434.s2.e1" text="clopidogrel" /><entity charOffset="119-128" id="DDI-PubMed.19845434.s2.e2" text="prasugrel" /><entity charOffset="139-150" id="DDI-PubMed.19845434.s2.e3" text="thiolactone" /><entity charOffset="338-349" id="DDI-PubMed.19845434.s2.e4" text="ticlopidine" /><pair ddi="false" e1="DDI-PubMed.19845434.s2.e0" e2="DDI-PubMed.19845434.s2.e0" /><pair ddi="false" e1="DDI-PubMed.19845434.s2.e0" e2="DDI-PubMed.19845434.s2.e1" /><pair ddi="false" e1="DDI-PubMed.19845434.s2.e0" e2="DDI-PubMed.19845434.s2.e2" /><pair ddi="false" e1="DDI-PubMed.19845434.s2.e0" e2="DDI-PubMed.19845434.s2.e3" /><pair ddi="false" e1="DDI-PubMed.19845434.s2.e0" e2="DDI-PubMed.19845434.s2.e4" /><pair ddi="false" e1="DDI-PubMed.19845434.s2.e1" e2="DDI-PubMed.19845434.s2.e1" /><pair ddi="false" e1="DDI-PubMed.19845434.s2.e1" e2="DDI-PubMed.19845434.s2.e2" /><pair ddi="false" e1="DDI-PubMed.19845434.s2.e1" e2="DDI-PubMed.19845434.s2.e3" /><pair ddi="false" e1="DDI-PubMed.19845434.s2.e1" e2="DDI-PubMed.19845434.s2.e4" /><pair ddi="false" e1="DDI-PubMed.19845434.s2.e2" e2="DDI-PubMed.19845434.s2.e2" /><pair ddi="false" e1="DDI-PubMed.19845434.s2.e2" e2="DDI-PubMed.19845434.s2.e3" /><pair ddi="false" e1="DDI-PubMed.19845434.s2.e2" e2="DDI-PubMed.19845434.s2.e4" /><pair ddi="false" e1="DDI-PubMed.19845434.s2.e3" e2="DDI-PubMed.19845434.s2.e3" /><pair ddi="false" e1="DDI-PubMed.19845434.s2.e3" e2="DDI-PubMed.19845434.s2.e4" /></sentence><sentence text=" Clopidogrel was shown to be a mechanism-based inhibitor of CYP2C19 with the inactivation kinetic parameters, k(inact) and K(I), equal to 0"><entity charOffset="1-12" id="DDI-PubMed.19845434.s3.e0" text="Clopidogrel" /></sentence><sentence text="0557 min(-1) and 14" /><sentence text="3 microM, respectively, as well as ticlopidine (0"><entity charOffset="35-46" id="DDI-PubMed.19845434.s5.e0" text="ticlopidine" /></sentence><sentence text="0739 min(-1) and 3" /><sentence text="32 microM, respectively)" /><sentence text=" The thiolactone metabolite of ticlopidine and clopidogrel inhibited CYP2C19 only in a concentration-dependent manner"><entity charOffset="5-16" id="DDI-PubMed.19845434.s8.e0" text="thiolactone" /><entity charOffset="31-42" id="DDI-PubMed.19845434.s8.e1" text="ticlopidine" /><entity charOffset="47-58" id="DDI-PubMed.19845434.s8.e2" text="clopidogrel" /><entity charOffset="69-76" id="DDI-PubMed.19845434.s8.e3" text="CYP2C19" /><pair ddi="false" e1="DDI-PubMed.19845434.s8.e0" e2="DDI-PubMed.19845434.s8.e0" /><pair ddi="false" e1="DDI-PubMed.19845434.s8.e0" e2="DDI-PubMed.19845434.s8.e1" /><pair ddi="false" e1="DDI-PubMed.19845434.s8.e0" e2="DDI-PubMed.19845434.s8.e2" /><pair ddi="false" e1="DDI-PubMed.19845434.s8.e0" e2="DDI-PubMed.19845434.s8.e3" /><pair ddi="false" e1="DDI-PubMed.19845434.s8.e1" e2="DDI-PubMed.19845434.s8.e1" /><pair ddi="false" e1="DDI-PubMed.19845434.s8.e1" e2="DDI-PubMed.19845434.s8.e2" /><pair ddi="false" e1="DDI-PubMed.19845434.s8.e1" e2="DDI-PubMed.19845434.s8.e3" /><pair ddi="false" e1="DDI-PubMed.19845434.s8.e2" e2="DDI-PubMed.19845434.s8.e2" /><pair ddi="false" e1="DDI-PubMed.19845434.s8.e2" e2="DDI-PubMed.19845434.s8.e3" /></sentence><sentence text=" In contrast, neither prasugrel nor its thiolactone metabolite inhibited CYP2C19 at concentrations up to 100 microM"><entity charOffset="22-31" id="DDI-PubMed.19845434.s9.e0" text="prasugrel" /><entity charOffset="40-51" id="DDI-PubMed.19845434.s9.e1" text="thiolactone" /><pair ddi="false" e1="DDI-PubMed.19845434.s9.e0" e2="DDI-PubMed.19845434.s9.e0" /><pair ddi="false" e1="DDI-PubMed.19845434.s9.e0" e2="DDI-PubMed.19845434.s9.e1" /></sentence><sentence text=" The oxidation of the thiophene moiety of clopidogrel to form their respective thiolactones was found to be the critical reaction that produces the chemically reactive metabolites which cause the mechanism-based inhibition of CYP2C19"><entity charOffset="22-31" id="DDI-PubMed.19845434.s10.e0" text="thiophene" /><entity charOffset="42-53" id="DDI-PubMed.19845434.s10.e1" text="clopidogrel" /><entity charOffset="79-91" id="DDI-PubMed.19845434.s10.e2" text="thiolactones" /><pair ddi="false" e1="DDI-PubMed.19845434.s10.e0" e2="DDI-PubMed.19845434.s10.e0" /><pair ddi="false" e1="DDI-PubMed.19845434.s10.e0" e2="DDI-PubMed.19845434.s10.e1" /><pair ddi="false" e1="DDI-PubMed.19845434.s10.e0" e2="DDI-PubMed.19845434.s10.e2" /><pair ddi="false" e1="DDI-PubMed.19845434.s10.e1" e2="DDI-PubMed.19845434.s10.e1" /><pair ddi="false" e1="DDI-PubMed.19845434.s10.e1" e2="DDI-PubMed.19845434.s10.e2" /></sentence><sentence text=" Estimation of in vivo drug-drug interaction using in vitro parameters predicted clinically observed data" /><sentence text=" For clopidogrel, there was no increase in the area under the curve (AUC) at its clinical dose level as predicted by the in vitro parameters, and for ticlopidine the prediction agreed with the clinically observed AUC increase"><entity charOffset="5-16" id="DDI-PubMed.19845434.s12.e0" text="clopidogrel" /><entity charOffset="150-161" id="DDI-PubMed.19845434.s12.e1" text="ticlopidine" /><pair ddi="false" e1="DDI-PubMed.19845434.s12.e0" e2="DDI-PubMed.19845434.s12.e0" /><pair ddi="false" e1="DDI-PubMed.19845434.s12.e0" e2="DDI-PubMed.19845434.s12.e1" /></sentence><sentence text=" In conclusion, clopidogrel is potent mechanism-based inhibitors of CYP2C19 as well as ticlopidine, whereas prasugrel did not inactivate CYP2C19"><entity charOffset="16-27" id="DDI-PubMed.19845434.s13.e0" text="clopidogrel" /><entity charOffset="87-98" id="DDI-PubMed.19845434.s13.e1" text="ticlopidine" /><entity charOffset="108-117" id="DDI-PubMed.19845434.s13.e2" text="prasugrel" /><pair ddi="false" e1="DDI-PubMed.19845434.s13.e0" e2="DDI-PubMed.19845434.s13.e0" /><pair ddi="false" e1="DDI-PubMed.19845434.s13.e0" e2="DDI-PubMed.19845434.s13.e1" /><pair ddi="false" e1="DDI-PubMed.19845434.s13.e0" e2="DDI-PubMed.19845434.s13.e2" /><pair ddi="false" e1="DDI-PubMed.19845434.s13.e1" e2="DDI-PubMed.19845434.s13.e1" /><pair ddi="false" e1="DDI-PubMed.19845434.s13.e1" e2="DDI-PubMed.19845434.s13.e2" /></sentence><sentence text=" Administration of prasugrel would not cause a clinically relevant interaction with CYP2C19"><entity charOffset="19-28" id="DDI-PubMed.19845434.s14.e0" text="prasugrel" /></sentence><sentence text="" /></document>